-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PGSTjwBviHGzA2f7899LJ9XAQiSasvM7D+JP29QZTyg5OBc4e5J94J/89nsrMujO 96iDrlz4mYMvvYKgIG3y/w== 0001104659-06-044072.txt : 20060628 0001104659-06-044072.hdr.sgml : 20060628 20060628141840 ACCESSION NUMBER: 0001104659-06-044072 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060620 ITEM INFORMATION: Other Events FILED AS OF DATE: 20060628 DATE AS OF CHANGE: 20060628 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOJECT MEDICAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0000810084 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 931099680 STATE OF INCORPORATION: OR FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15360 FILM NUMBER: 06929534 BUSINESS ADDRESS: STREET 1: 20245 SW 95TH AVENUE CITY: TUALATIN STATE: OR ZIP: 97062 BUSINESS PHONE: 5036928001 MAIL ADDRESS: STREET 1: 20245 SW 95TH AVENUE CITY: TUALATIN STATE: OR ZIP: 97062 FORMER COMPANY: FORMER CONFORMED NAME: BIOJECT MEDICAL SYSTEMS LTD DATE OF NAME CHANGE: 19920703 8-K 1 a06-14598_18k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  June 20, 2006

 

BIOJECT MEDICAL TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

 

Commission File Number:  0-15360

 

Oregon

 

93-1099680

(State or other jurisdiction of incorporation

 

(I.R.S. Employer Identification No.)

or organization)

 

 

 

 

 

20245 SW 95th Avenue

 

 

Tualatin, Oregon

 

97062

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (503) 692-8001

 

Former name or former address if changed since last report:

No Change

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



 

BIOJECT MEDICAL TECHNOLOGIES INC.

FORM 8-K

INDEX

 

Item

 

Description

 

 

 

 

 

Item 8.01

 

Other Events

 

 

 

 

 

Signatures

 

 

 

 

1



 

Item 8.01  Other Events

On June 20, 2006, Bioject Medical Technologies Inc. (“Bioject”) terminated its agreement for future services with the contract filler of its Iject® prefilled device. The original agreement, entered into on September 30, 2003, was for the design of a sterile fill suite to house Bioject filling equipment and contract filling services through 2009. This termination, which is effective September 30, 2006, was due to Bioject’s decision to switch to a more cost effective commercial filling method and potential customers interest in doing their own filling. This contract, if not terminated, would have required Bioject to pay approximately $2.1 million for services over the next three years. As a result of this termination, Bioject is currently evaluating its assets located at the contract filler’s facility for impairment. Bioject anticipates that a portion of the filling equipment will be moved to its ISO 8 clean room located in Tualatin, Oregon and will be utilized for small batch and clinical fills. The book value of these assets was approximately $1.3 million as of June 20, 2006.

2



 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: June 28, 2006

 

BIOJECT MEDICAL TECHNOLOGIES INC.

 

 

(Registrant)

 

 

 

 

 

 

 

 

/s/ CHRISTINE M. FARRELL

 

 

 

Christine M. Farrell

 

 

Vice President of Finance

 

 

(Principal Financial and Accounting Officer)

 

3


 -----END PRIVACY-ENHANCED MESSAGE-----